Clinical outcomes, toxicity, and cosmesis in breast cancer patients with close skin spacing treated with accelerated partial breast irradiation (APBI) using multi-lumen/catheter applicators

Akhtari, Mani; Abboud, Mirna; Szeja, S.; Pino, Ramiro; Lewis, Gary D.; Bass, Barbara L.; Miltenburg, Darlene M.; Butler, E. Brian; Teh, Bin S.

doi:10.5114/jcb.2016.64830

Cited by 6 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…analyzed a group of patients treated with Contura ® (Contura ® Multi-Lumen Balloon, SenoRx, Inc., Aliso Viejo, CA, USA) or Savi ® (Strut-Adjusted Volume Implant, Cianna Medical, Aliso Viejo, CA, USA). When the distance to skin was smaller or equal to 3 mm, up to 128.8% of the dose prescribed have reached the skin, increasing acute and chronic toxicity [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results

Latorre¹,

Galdós²,

Buznego³

et al. 2018

jcb

View full text Add to dashboard Cite

PurposeTo evaluate the feasibility of acute and chronic toxicity in patients suitable for accelerated partial breast irradiation (APBI) in a single 18 Gy fraction with multicatheter high-dose-rate (HDR) brachytherapy, as well as cosmetic and oncological outcomes.Material and methodsBetween September 2014 and March 2016, twenty consecutive patients with low-risk invasive and ductal carcinoma in situ were treated with interstitial multicatheter HDR brachytherapy in a single 18 Gy fraction.ResultsMedian age was 63.5 years (range, 51-79). Acute toxicity was observed in seven patients, while the pain during following days and hematoma were seen in four patients. With a median follow-up of 24 months, late toxicity was found in one patient with fat necrosis g2 and fibrosis g2 in another patient. The overall survival (OS) and locoregional control (LC) was 100%. Disease-free survival (DFS) and distant control was 95%. Good to excellent cosmetic outcomes were noted in 80% of patients and fair in 4 patients (20%).ConclusionsThis is the first report in the medical literature that focuses on feasibility and acute and chronic toxicity, with a median follow-up of 24 months (range, 20-40). The protocol is viable and convenient. However, a longer follow-up is needed to know chronic toxicity and oncologic outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results

Latorre¹,

Galdós²,

Buznego³

et al. 2018

jcb

View full text Add to dashboard Cite

show abstract

“…Akhtari et al analyzed a group of patients treated with Contura ® (Contura ® Multi-Lumen Balloon, SenoRx, Inc., Aliso Viejo, CA, USA) or Savi ® (Strut-Adjusted Volume Implant, Cianna Medical, Aliso Viejo, CA, USA). When the distance to skin was smaller or equal to 3 mm, up to 128.8% of the dose prescribed have reached the skin, increasing acute and chronic toxicity [32].…”

Section: Discussionmentioning

confidence: 99%

Faculty Opinions recommendation of Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results.

Livi

Desideri

2020

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature

View full text Add to dashboard Cite

Purpose: To evaluate the feasibility of acute and chronic toxicity in patients suitable for accelerated partial breast irradiation (APBI) in a single 18 Gy fraction with multicatheter high-dose-rate (HDR) brachytherapy, as well as cosmetic and oncological outcomes. Material and methods: Between September 2014 and March 2016, twenty consecutive patients with low-risk invasive and ductal carcinoma in situ were treated with interstitial multicatheter HDR brachytherapy in a single 18 Gy fraction. Results: Median age was 63.5 years (range, 51-79). Acute toxicity was observed in seven patients, while the pain during following days and hematoma were seen in four patients. With a median follow-up of 24 months, late toxicity was found in one patient with fat necrosis g2 and fibrosis g2 in another patient. The overall survival (OS) and locoregional control (LC) was 100%. Disease-free survival (DFS) and distant control was 95%. Good to excellent cosmetic outcomes were noted in 80% of patients and fair in 4 patients (20%). Conclusions: This is the first report in the medical literature that focuses on feasibility and acute and chronic toxicity, with a median follow-up of 24 months (range, 20-40). The protocol is viable and convenient. However, a longer follow-up is needed to know chronic toxicity and oncologic outcomes.

show abstract

“…Excellent cosmetic outcomes with acceptable toxicity profile was reported by Akhtari et al . in their APBI series using single-entry multi-lumen/catheter applicators with skin spacing of ≤ 7 mm [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Should molecular subtype be recommended as one of the selection criteria for accelerated partial breast irradiation? Preliminary results from an Asian cohort

Wadasadawala

Mondal

Paul

et al. 2018

jcb

View full text Add to dashboard Cite

PurposeThe purpose of this study was to report clinical outcomes in patients treated with accelerated partial breast irradiation (APBI), stratified as per molecular subtype and American Society for Therapeutic Radiology and Oncology/Groupe Européen de Curiethérapie and European Society for Radiotherapy & Oncology (ASTRO/GEC-ESTRO) patient selection criteria in order to determine whether molecular subtype should be recommended as one of the selection criteria for APBI.Material and methods157 early-stage breast cancers patients, treated with APBI using multi-catheter interstitial brachytherapy with ≥ 6 months follow-up were included. Molecular subtype was assigned based on estrogen/progesterone receptor (ER/PR), Her2neu and tumor grade. Patients were stratified into ASTRO and GEC-ESTRO risk groups, as per updated ASTRO consensus statement (CS) and GEC-ESTRO recommendation, respectively. The Kaplan-Meier method was used to calculate the time to event data of clinical outcomes.ResultsWith a median follow-up of 35 months, local control (LC) and locoregional control (LRC) were not significantly different among the different molecular subtypes (p = 0.19, p = 0.41, respectively). None of the APBI guidelines predicted risk of local or locoregional recurrence. Re-analyzing the data by replacing ER status with molecular subtype in the ASTRO-CS did not show any significant difference in LC/LRC across the various categories. Her2neu subtype was associated with significantly lower disease-free survival, cause specific survival, and overall survival than the luminal subtypes.ConclusionsNone of the mentioned APBI guidelines predicted local or locoregional recurrence risk in our study population. Additional follow-up will be needed to recommend inclusion of molecular subtype (or at least HER2 receptor status) in the patient selection criteria for APBI.

show abstract

Clinical outcomes, toxicity, and cosmesis in breast cancer patients with close skin spacing treated with accelerated partial breast irradiation (APBI) using multi-lumen/catheter applicators

Cited by 6 publications

References 18 publications

Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results

Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results

Faculty Opinions recommendation of Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results.

Should molecular subtype be recommended as one of the selection criteria for accelerated partial breast irradiation? Preliminary results from an Asian cohort

Contact Info

Product

Resources

About